Unicycive Announces Acceptance of Two Preclinical Data Sets to be Presented at the European Renal Association Congress LOS ALTOS, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today...